Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries

Joana Cortez, Rui Providência, Evelise Ramos, Cristina Valente, Jorge Seixas, Manuela Meruje, António Leitão-Marques, António Vieira

Abstract
Due to recent population emigration movements, an epidemic of Chagas disease is currently menacing most developed countries. The authors report the case of a 53-year-old Brazilian woman living in Europe for the last 10 years who developed heart failure symptoms, having a previous symptomatic sinus node disease with a pacemaker implant at age of 40 years. The diagnosis was based on serology and myocardial biopsy and the patient was treated with nifurtimox. The authors emphasize the need of a high level of suspicion in patients with suggestive epidemiology and the need of populational screening of specific high risk groups. New treatment options are also discussed.

INTRODUCTION
Chagas disease (CD) is one of the parasitic diseases with a high economic burden throughout Latin America. It affects around 10 million people and has now become global due to recent population movements and migration. Being one of the 17 neglected tropical diseases, it still affects the poor and “promotes poverty”. Its presence outside Latin America is primarily the result of migration but it has also been reported among travellers and in adopted children. Important transmission routes in Europe are transfusion, vertical or organ transplantation. The challenge in treatment of chronic CD is due to limitations of the currently available specific treat-
ments, benznidazole and nifurtimox, and also to the lack of biological markers for the early evaluation of antiparasitic drug efficacy and clinical response\[^3\]. Chronic chagasic cardiomyopathy (CCC) is the most serious and common etiology of CCC in Latin America and occurs in 20%-30% of infected subjects, usually 10-30 years after infection by *Trypanosoma cruzi*\[^4\].

In this report, we emphasize the implications of a very great latent time until CD diagnosis and emergent opportunities in treatment and surveillance programs. A brief presentation of new therapeutic options is also presented at the end of the paper.

**CASE REPORT**

In January 2011, a 53-year-old Brazilian woman was referred for assessment in our Cardiology Clinic and Infectious Diseases Department due to complaints of heart failure and after taking into account her epidemiological background.

She had experienced worsening dyspnea with marked limitation of activity and orthopnea for the last 3 mo, and was currently graded as class III New York Heart Association (NYHA). She denied any gastrointestinal symptoms or constitutional symptoms.

Her comorbidities were diabetes and hypertension. Moreover, in 2002 she was diagnosed with symptomatic (syncopal) sinus node disease, presenting with sinus bradycardia of 40 beats/min and frequent sinus pauses and non-sustained ventricular tachycardia with runs of less than 5 beats. At that time, echocardiography revealed normal left ventricular systolic function and no further relevant changes. A DDD-R permanent pacemaker was then implanted and some years later she was lost to follow-up. She was currently medicated with metformin/sitagliptin, an angiotensin receptor blocker and nitrates.

She had lived in a rural area in the Goiás state of Brazil, located in the central part of the country, until the age of 12 years. Her family house was a typical one in the vicinity. No bed nets were used for protection. She had one blood transfusion during her first delivery (age 25 years). Her mother died when she was 60 years old and was currently graded as NYHA III. Her two sons (30 and 31 years old, respectively) were screened for CD using ELISA and IFAT and they were both negative. The patient started antitrypanosomal therapy with nifurtimox 10 mg/kg per day, administered orally in four divided doses, for 90 d. Side-effects were significant: 12 kg weight loss, decreased short-term memory, nausea, headache, dizziness and mood changes.

Despite this, the patient strictly complied with her treatment. Monitoring of blood count, hepatic enzymes, serum creatinine, and urea was performed before, monthly and at end of treatment. One month after the end of treatment anti-*T. cruzi* antibodies were still detected by IFAT and ELISA and nested-PCR for *T. cruzi* was inconclusive.

No improvement was observed in the patient's ejection fraction, which remained stable at 12-mo follow-up. She is currently graded as NYHA II on regular follow-up at the Cardiology and Infectious Diseases clinics in our hospital. She has been advised not to donate blood or organs in the future and not to undergo further pregnancies due to the risk of transmission.

**DISCUSSION**

In Portugal, CD is an emerging imported parasitosis. According to the World Health Organization (WHO) Working Group on Chagas disease, there are an estimated 1255 people infected with *T. cruzi* (prevalence rate of 1%) in Portugal, but only 8 cases have been diagnosed by laboratory testing\[^1\]. Unfortunately, all these cases were lost to follow-up. Our patient is the ninth to be diagnosed. This means an index of underdiagnosis of 99.4%. The index of underdiagnosis of the other eight European countries that participated in that surveillance study shows that, in general, between 95% and 96% of expected cases are not diagnosed\[^1\]. This enormous percentage is probably due to illegal immigrants and due to the fact of limited experience in the detection and man-
agement of CD of most European health professionals.

In the Northern Goiás State of Brazil, where our patient was born, the presence of triatomides in dwellings or evidence of triatomide colonization was found to be statistically correlated with seropositivity in children[5].

Our case report could be a vector-borne transmission supported by the very typical correlation with mud houses, such as the one inhabited by our patient during her childhood. Less likely, it could have been a blood-borne infection due to transfusion. It seems unlikely to be a congenital transmission since the mortality rate among such infected children is very high, mainly due to acute meningoencephalitis and myocarditis, and this transmission is greatly related to abortion and low-birth weight[6].

The most frequent ECG finding in CD individuals is the presence of right bundle branch block alone or in association with left anterior fascicular block. Other ECG changes are also frequent, such as atrial and ventricular premature beats, intraventricular or atrioventricular conduction disturbances, and primary ST-T wave changes[7].

Sinus bradycardia and chronotropic incompetence are therefore common in these patients. In more advanced disease states, marked atrial remodeling and dilatation alongside atrial arrhythmias may also occur[8].

Congestive heart failure and sudden cardiac death are the main causes of death among chagasic patients. The average prevalence of malignant arrhythmias in these patients is unknown, but risk factors have been identified: regional contractile abnormalities and mild left ventricle dysfunction[9], apical lesions[10], moderate or severe LV systolic dysfunction[11], exercise-induced ventricular arrhythmia[12], non-sustained ventricular arrhythmia[13], New York Heart Association functional class III-IV and absence of β-blocker treatment[14].

According to the I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy[15], the patient’s drug therapy would have the following classes of recommendation and levels of evidence: angiotensin receptor blocker (I-C); β-blocker, oral anti-coagulants (I-C); amiodarone (I-B); and nitrate (II-a-C). Further therapy can be introduced in the future if the patient develops congestive symptoms and deteriorates into III or IV NYHA class: spironolactone (I-B); diuretic (II-a-C); digitalis (II-a-C).

Digitalis, angiotensin-converting enzyme inhibitors[16] and beta-blockers[17] have proven to be useful in reducing neurohormonal activation in patients with advanced Chagas cardiomyopathy.

The implantable cardiac defibrillator (ICD) has proven to be effective in terminating life-threatening arrhythmias, in a registry including mostly patients under secondary prevention[18]. These patients have a very high

![Figure 1 Transthoracic echocardiogram: apical 4-chamber view (A), parasternal long-axis (B); and (C) left ventricle angiogram showing a dilated and aneurysmatic left ventricle (36.37 mm²/m² end diastolic and 31.44 mm²/m² end systolic diameter) with generalized hypokinesia.](image1)

![Figure 2 T. cruzi pseudocyst (arrow). A: Heart muscle, Giemsa staining, 100×; B: Heart muscle, hematoxylin-eosin staining, 100×.](image2)
incidence of electrical storms, reaching 15.7% in an ICD registry[21].

Patients should be selected for this type of therapy according to the international guidelines[22]. However, some authors propose that patients with non-sustained ventricular arrhythmia without straight indication for ICD should be referred for programmed ventricular stimulation[23]. Radiofrequency ablation is another option for treating these patients, but sometimes an epicardial approach may be necessary in order to more effectively target the arrhythmia substrate[24].

According to the scoring system defined by Rassi et al[25], this patient would be assigned 15 points based on: NYHA III class (5 points), cardiomegaly on chest X-ray (5 points), LV systolic dysfunction on echocardiography (3 points) and non-sustained ventricular tachycardia on 24-h Holter monitoring (2 points). This score puts her in the high-risk category (risk of death in the next 10 years of 84%).

PCR for T. cruzi was not performed initially because serology is the gold-standard for diagnosis of chronic CD[26-29], despite being affected by cross-reactions with antibodies induced by other parasites, namely Leishmania and T. rangeli[30]. Due to this, two different serologic tests were performed to confirm the results. PCR is used for post-treatment follow-up to look for failure of therapy in achieving parasitological response, but its variability in sensitivity may be explained by the intermittent presence and quantity of circulating parasites at the time of blood collection[29].

Our patient was not cured as antibody titres did not decrease significantly and did not become negative. However, this result is often not observed until 8 to 10 years post-treatment and then only in approximately 15% of treated adult subjects[31]. The main impact of the great latent time until the diagnosis of CCC is the lack of efficacy of the two approved drugs for antitrypanosomal therapy in chronically-infected patients. Conversely, in acute disease the cure rate is reported to be around 85%[32] and in congenital transmission it can reach 100%[33]. It is clear that efficacy declines markedly with the duration of infection[3]. Uncertainty remains regarding the degree of efficacy, mainly because of the lack of a reliable test of cure, as explained above.

The reason why this patient was treated with nifurtimox was due to WHO stock shortage of benznidazole, which seems to be a better tolerated drug[30]. The Benznidazole Evaluation for Interrupting Trypanosomiasis, a large, multicenter, double-blind, randomized, placebo-controlled trial of benznidazole for patients with mild-to-moderate CCC, is ongoing and the results will not be known until end of 2012[31]. Despite most physicians often being reluctant to treat patients with CCC who are above 50 years of age because of the frequent side effects, the inability to confirm cure conclusively, and lack of efficacy of the two currently available drugs, some authors have shown a reduction in the rate of progression toward advanced cardiopathy compared to untreated patients[14,30,31]. It is obvious that new treatments are urgently needed, and the antifungal triazoles, namely posaconazole, have demonstrated potential for therapeutic switching[13,30,32]. Unfortunately, only one clinical case has been published of a previous treatment failure with benznidazole and subsequent successful treatment with posaconazole using PCR as follow-up[3].

In the face of relative unsuitability of Chagas patients for heart transplant due to the risks of increased parasitemia when under immunosuppression, the possibility of using stem cells to treat chagasic cardiomyopathy has been viewed with enthusiasm[33].

In 2004, Soares et al[34] demonstrated that intravenous injection of bone marrow cells into chronic chagasic mice resulted in migration to the heart and a significant reduction in inflammatory infiltrates and interstitial fibrosis. Guarita-Souza et al[35] have administered autologous skeletal myoblasts and mesenchymal stem cells from bone marrow to Wistar rats and observed a significant improvement in LV ejection fraction and reduction in LV end-systolic and end-diastolic function. Similar changes were found by another group using bone marrow cells in mice[36]. It has been recently proposed that the beneficial immunomodulatory effect of this therapy may be related to transcriptomic recovery, a measure of the genes that are either up- or downregulated by the presence of the disease[37]. The first clinical trial was conducted by the group of Vilas-Boas and colleagues in 28 patients using autologous bone marrow cells. A significant improvement during an 180-d follow-up was observed in LV ejection fraction (20.1% ± 6.8% to 28.3% ± 7.9%; P < 0.03), NYHA functional class (3.1 ± 0.3 to 1.8 ± 0.5; P < 0.001), Minnesota quality of life questionnaire (50.9 ± 11.7 to 25.1 ± 15.9; P < 0.001) and 6-min walk test[38]. Nevertheless, a larger randomized, double-blind, placebo-controlled clinical trial is needed.

Chagas disease is associated with heart failure, the presence of left ventricular apical aneurysm, left atrial dysfunction, cardiac arrhythmias, a proinflammatory status and several other factors that predispose to stroke[39,40]. Furthermore, the presence of Chagas disease is in itself an independent risk factor for stroke[41]. The possible existence of a prothrombotic disease state is still controversial[42,43]. Sometimes, stroke can be the first sign of Chagas disease in asymptomatic patients or in those with mild systolic dysfunction[44]. Recurrence is estimated to be around 20%, so secondary prevention is recommended[39]. No randomized studies have been conducted so far regarding the role of anticoagulation for primary prevention of thromboembolism in Chagas disease. However, Sousa et al[45] have developed a cardioembolic risk score including 4 variables: systolic dysfunction (2 points), apical aneurism (1 point), primary alteration on ventricular repolarization (1 point) and age > 48 years (1 point). According to this score, our patient would achieve 4 points, placing her under a risk category that has an annual stroke rate of 4.4% and therefore has benefit from oral anticoagulation. The
decision to use aspirin or warfarin to prevent thromboembolism in these patients remains an open and challenging question.\(^\text{[39]}\)

Another interesting issue regarding chagasic therapy is the role of supplementation with selenium (Se), which is an essential micronutrient and an antioxidant at the cellular level.\(^\text{[40]}\) Data from Souza et al.\(^\text{[33]}\) indicate that Se treatment prevents right ventricular chamber increase and thus can be proposed as an adjuvant therapy for cardiac alterations already established by *T. cruzi* infection. Moreover, this author had previously demonstrated that a Se-deficient diet contributed to an increased susceptibility to this infection in experimental models and higher mortality during *T. cruzi* infection,\(^\text{[38]}\) whereas oral Se supplementation at low doses alleviated heart damage.\(^\text{[39]}\)

The index of underdiagnosis estimated for eight European countries with culture and linguistic proximity to Latin American countries is a good indicator of the limited epidemiological impact of CD in the context of European health and surveillance systems. Since subjects with CD have low economic resources, the pharmaceutical companies are not particularly interested in supporting research and development of new drugs. Delay in diagnosis may result in progression of cardiac disease. New therapeutic options are promising a better future for CD, but their efficacy and safety still need to be tested. The priority should be the implementation of screening programs for target populations (women of childbearing age and a high suspicion level in young patients with heart failure or dysrhythmias at risk of having been infected earlier in endemic countries) and the training of professionals in the detection of possible cases, as well as implementation of rigorous protocols for blood and organ donation, are essential to limit the impact of Chagas disease in countries where there is no vector transmission.

ACKNOWLEDGMENTS

The authors would like to thank Olga Matos, PhD, for technical assistance.

REFERENCES

1 Basile L, Jansa JM, Carlier Y, Salamanca DD, Angeheben A, Bartoloni A, Seixas J, Van Gool T, Canavate C, Flores-Chavez M, Jackson Y, Chiodini PL, Albijar-Vinas P. Chagas disease in European countries: the challenge of a surveillance system. *Euro Surveill* 2011; 16: pii p1968

2 First WHO report on neglected tropical diseases: Working to overcome the global impact of neglected tropical diseases. Available from: URL: www.who.int/neglected_diseases/2010report/en/

3 Pinazo MJ, Espinosa G, Gallego M, López-Chajeda PL, Urbina JA, Gasco J. Successful treatment with posaconazole of a patient with chronic Chagas disease and systemic lupus erythematosus. *Am J Trop Med Hyg* 2010; 82: 583-587

4 Rassi A, Rassi A, Marin-Neto JA. Chagas disease. *Lancet* 2010; 375: 1388-1402

5 Telleria J, Tibayrenc M. American Trypanosomiasis: Chagas Disease One Hundred Years of Research (Elsevier Insights).

1st ed. Amsterdam: Elsevier, 2010: 531-532

6 Flores-Chávez M, Faez Y, Olalla JM, Cruz I, Gárate T, Rodríguez M, Blanc P, Castañuca C. Fatal congenital Chagas’ disease in a non-endemic area: a case report. *Cases J* 2008; 1: 302

7 Elizari MV, Chiale PA. Cardiac arrhythmias in Chagas’ heart disease. *J Cardiacolect. Electrofisiol 1993; 4: 596-608

8 Caio T, Iosa D. Chronic Chagas’ disease: possible mechanism of sinus bradydysrythm. *Can J Cardiol* 1994; 10: 765-768

9 Carrasco HA, Mora R, Inglessis G, Contreras JM, Marval J, Fuenmayor A. [Study of sinus node function and atrioventricular conduction in patients with chagas disease (author’s trans)]. *Arch Cardiol Mex* 1982; 52: 245-251

10 Altschüller MB, Pedrosa RC, Pereira Bde B, Corrêa Filho WB, Medeiros AS, Costa PC, de Carvalho AC. [Chronic Chagas disease patients with sinus node dysfunction: is the presence of IgG antibodies with muscarinic agonist action independent of left ventricular dysfunction?]. *Rev Soc Bras Med Trop* 2007; 40: 665-671

11 Benchimol-Barbosa PR, Barbosa-Filho J. Atrial mechanical remodeling and new onset atrial fibrillation in chronic Chagas’ heart disease. *Int J Cardiol* 2008; 127: e113-e115

12 Terzi FV, Siqueira Filho AG, Nascimento EM, Pereira Bde B, Pedrosa RC. [Regional left ventricular dysfunction and its association with complex ventricular arrhythmia, in chagasic patients with normal or borderline electrocardiogram]. *Rev Soc Bras Med Trop* 2010; 43: 557-561

13 Gurgel CB, Ferreira MC, Mendes CR, Cuntoino E, Favoritto P, Carneiro F. [Atrial lesions in Chagas’ heart disease patients: an autopsy study]. *Rev Soc Bras Med Trop* 2010; 43: 709-712

14 Sarabanda AV, Marin-Neto JA. Predictors of mortality in patients with Chagas’ cardiomyopathy and ventricular tachycardia not treated with implantable cardioverter-defibrillators. *Pacing Clin Electrophysiol* 2011; 34: 54-62

15 Pedrosa RC, Salles JH, Magnanini MM, Bezerra DC, Bloch KV. Prognostic value of exercise-induced ventricular arrhythmia in Chagas’ heart disease. *Pacing Clin Electrophysiol* 2011; 34: 1492-1497

16 Silva RM, Távora MZ, Gondim FA, Metha N, Hara VM, Paola AA. Predictive value of clinical and electrophysiologic variables in patients with chronic chagasic cardiomyopathy and nonsustained ventricular tachycardia. *Arq Bras Cardiol* 2000; 75: 35-47

17 Flores-Ocampo J, Nava S, Marquez MF, Gómez-Flores J, Colín L, López A, Celaya M, Treviño E, González-Hermoislo JA, Iturralde P. [Clinical predictors of ventricular arrhythmia storms in Chagas cardiomyopathy patients with implantable defibrillators]. *Arch Cardiol Mex* 2009; 79: 263-267

18 Andrade JP, Marin-Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, Bocchi EA, Almeida DR, Fragata Filho AA, Moreira Mda C, Xavier SS, Oliveira Junior WA, Dias JCA. [I Latin American guidelines for the diagnosis and treatment of Chagas cardiomyopathy]. *Arq Bras Cardiol* 2011; 97: 1-48

19 Khoury AM, Davila DF, Bellabarba G, Donis JH, Torres A, Lemorvan C, Hernandez L, Bishop W. Acute effects of digoxin, enalapril and cilostazol and enalapril on the neurohormonal profile of chagasic patients with severe congestive heart failure. *Int J Cardiol* 1996; 57: 21-29

20 Davila DF, Angel F, Arata de Bellabarba G, Donis JH. Effects of metoprolol in chagasic patients with severe congestive heart failure. *Int J Cardiol* 2002; 85: 255-260

21 Muratore CA, Battista Sa LA, Chiale PA, Eloy R, Tentori MC, Escudero J, Lima AM, Medina LE, Garrett R, Maloney J. Implantable cardioverter defibrillators and Chagas’ disease: results of the ICD Registry Latin America. *Eurosurv* 2009; 11: 164-168

22 Epstein AE, D’im Marco JP, Ellenbogen KA, Estes NA, Freedman RA, Gettes LS, Gillinov AM, Gregoratos G, Hammill SC, Hayes DL, Hlatky MA, Newby LR, Page RL, Schoenfield
planted bone marrow cells repair heart tissue and reduce myopathy. 

PLoS Negl Trop Dis 2010; 4: e484

Benn C. Antitrypanosomal therapy for chronic Chagas’ disease. N Engl J Med 2011; 364: 2527-2534

Bernini-Ja Neto JA, Rassi A, Morillo CA, Avezum A, Connolly SJ, Sosa-Estani S, Rosas FY, Yusuf S. Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas’ cardiomyopathy: the BENZimidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). Am Heart J 2008; 156: 37-43

Ribeiro I, Sevsic AM, alves F, Diap G, Don R, Harhary MO, Chang S, Pecoul B. New, improved treatments for Chagas disease: from the R&D amp, D pipeline to the patients. PLoS Negl Trop Dis 2009; 3: e484

Muratore CA, Baranchuk A. Current and emerging therapeutic options for the treatment of chronic chagasic cardiomyopathy. Vasc Health Risk Manag 2010; 6: 593-601

Soares MB, Lima RS, Rocha LL, Takuya CM, Pontes-de Carvalho L, de Carvalho AC, Ribeiro-dos-Santos R. Transplanted bone marrow cells repair heart tissue and reduce myocarditis in chronic chagasic mice. Am J Pathol 2004; 164: 441-447

Guarita-Souza LC, Carvalho KA, Wotowicz V, Rebelatto C, Senegaglia A, Hansen P, Miyague N, Francisco JC, Ollendoski M, Tamasato NA, Brotman P. Simultaneous autologous transplantation of cocultured mesenchymal stem cells and skeletal myoblasts improves ventricular function in a murine model of Chagas disease. Circulation 2006; 114: 1120-1124

Goldenberg RC, Jerlicks LF, Fortes FS, Weiss LM, Rocha LL, Zhao D, Carvalho AC, Spray DC, Tanowitz HB. Bone marrow cell therapy ameliorates and reverses chagasic cardiomyopathy in a mouse model. J Infect Dis 2008; 197: 544-547

Soares MB, Lima RS, Souza BS, Vasconcelos JF, Rocha LL, dos Santos RR, Iacobas SG, Goldenberg RC, Lisanti MP, Iacobas DA, Tanowitz HB, Spray DC, Carvalho AC. Reversion of gene expression alterations in hearts of mice with chronic chagasic cardiomyopathy after transplantation of bone marrow cells. Cell Cycle 2011; 10: 1448-1455

Villas-Boas F, Feitosa GS, Soares MB, Pinho-Filho JA, Mota AC, Almeida AJ, Andrade MV, Carvalho HG, Oliveira AD, Ribeiro-dos-Santos R. Bone marrow cell transplantation in Chagas’ disease heart failure: report of the first human experience. Arq Bras Cardiol 2011; 96: 325-331

Cardó-Artal FJ, Gascon J. Chagas disease and stroke. Lancet Neurol 2010; 9: 533-542

Mancuso FJ, Almeida DR, Moisés VA, Oliveira WA, Mello ES, Pooyanes D, Tufik S, Carvalho AC, Campos O. Left atrial dysfunction in chagas cardiomyopathy is more severe than in idiopathic dilated cardiomyopathy: a study with real-time three-dimensional echocardiography. J Am Soc Echocardiogr 2011; 24: 526-532

Paixão LC, Ribeiro AL, Valacio RA, Teixeira AL. Chagas disease: independent risk factor for stroke. Stroke 2009; 40: 3691-3694

Pinazo MJ, Tassies D, Muñoz J, Fisa R, Posada Ede J, Monteagudo J, Ayala E, Gállego M, Reverter JC, Gascon J. Hypercoagulability biomarkers in Trypanosoma cruzi-infected patients. Thromb Haemost 2011; 106: 617-623

Melo LM, Souza GE, Valim LR, Moreira LF, Damico EA, Rocha TR, Barretto AC, Strunz CM, Bocchi EA, Ramires JA. Study of pro-thrombotic and pro-inflammatory factors in Chagas cardiomyopathy. Arq Bras Cardiol 2010; 95: 655-662

Caró-Artal FJ, Vargas AP, Falcao T. Stroke in asymptomatic Trypanosoma cruzi-infected patients. Cerebrovasc Dis 2011; 31: 24-29

Sousa AS, Xavier SS, Freitas GR, Hasslocher-Moreno A. Prevention strategies of cardioembolic ischemic stroke in Chagas’ disease. Arq Bras Cardiol 2008; 91: 306-310

Jerlicks LA, de Souza AP, Araújo-Jorge TC, Tanowitz HB. Would selenium supplementation aid in therapy for Chagas disease? Trends Parasitol 2011; 27: 102-105

Souza AP, Jerlicks LA, Tanowitz HB, Olivieri BP, Medeiros MM, Oliveira GM, Pires AR, Santos AM, Araújo-Jorge TC. The benefits of using selenium in the treatment of Chagas disease: prevention of right ventricle chamber dilatation and reversion of Trypanosoma cruzi-induced acute and chronic cardiomyopathy in mice. Mem Inst Oswaldo Cruz 2010; 105: 746-751

de Souza AP, Melo de Oliveira G, Nêve J, Vanderpas J, Pirmez C, de Castro SL, Araújo-Jorge TC, Rivera MT. Trypanosoma cruzi host selenium deficiency leads to higher mortality but similar parasitemia in mice. Exp Parasitol 2002; 101: 193-199

de Souza AP, de Oliveira GM, Vandenbos J, de Castro SL, Rivera MT, Araújo-Jorge TC. Selenium supplementation at low doses contributes to the decrease in heart damage in experimental Trypanosoma cruzi infection. Parasitol Res 2003; 91: 51-54